• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    ProMetic Secures $30 Million Follow-on Financing

    Vivien Diniz
    Mar. 01, 2016 09:39AM PST
    Biotech Investing

    ProMetic Life Sciences Inc. (TSX:PLI, OTCQX:PFSCF) has secured a follow-on investment from Structured Alpha LP, an affiliate of Peter J. Thomson’s investment firm, Thomvest Asset Management Inc., consisting of a $30 million original issue discount note.

    ProMetic Life Sciences Inc. (TSX:PLI, OTCQX:PFSCF) has secured a follow-on investment from Structured Alpha LP, an affiliate of Peter J. Thomson’s investment firm, Thomvest Asset Management Inc., consisting of a $30 million original issue discount note.
    Stefan Clulow, Managing Director and Chief Investment Officer at Thomvest Asset Management Inc. commented:

    We are very pleased to provide more support to ProMetic as it continues to deliver on its operational and clinical milestones. Since our initial investment inSeptember 2013, ProMetic has transitioned from a development stage company to an integrated biopharmaceutical company that is advancing a broad array of small molecule and plasma-derived clinical assets. We are confident that ProMetic will be successful in monetizing its innovations and we look forward to participating further in the significant value creation we see unfolding as ProMetic’s product pipeline continues to grow and approach the commercialization stage.

    Commenting on Structured Alpha’s follow-on investment, Mr. Pierre Laurin, President and Chief Executive Officer of ProMetic Life Sciences Inc., said:

    We are delighted that Mr. Thomson has decided to deepen his relationship with ProMetic. Our strategic relationship has already allowed for the operational launch of our plasma purification facility, the accelerated development of our plasma derived and small molecule technology platforms and advancement of our clinical programs. We look forward to leveraging this follow-on investment to generate value for all our shareholders.

    Click here to view the full press release. 
     

    clinical milestones
    The Conversation (0)

    Go Deeper

    AI Powered
    Test tubes.

    Biotech Market Forecast: Top Trends for Biotech in 2025

    TSXV:SBM

    Sirona Biochem Secures Strategic Investment Agreements and New Joint Venture with Promura GmbH

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×